Drug-drug interactions and drug resistance will limit access to treatment in patients with HIV and hepatitis C virus coinfection

Clinical Infectious Diseases

Volumn 57, Issue 1, 2013, Pages 156-157

  Marks, Michael ^a   Kulasegaram, Ranjababu ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; INTEGRASE INHIBITOR; PROTEINASE INHIBITOR;

DRUG SAFETY; GENOTYPE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MIXED INFECTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTI-HIV AGENTS; FEMALE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; PROLINE; PROTEASE INHIBITORS;

EID: 84878886320     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit168     Document Type: Letter

References (4)

1. Hulskotte EG, Feng HP, Xuan F, et al Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir. Clin Infect Dis 2013; 56: 718-26.
2. Joshi D, O'Grady J, Dieterich D, Gazzard B, Agarwal K. Increasing burden of liver disease in patients with HIV infection. Lancet 2011; 377:1198-209.
3. The Sprint 2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1195-206.
4. Steigbiel RT. Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 phase III trials. Clin Infect Dis 2010; 50:605-12.